Sodium channels and nociception: recent concepts and therapeutic opportunities
Krafte DS, Bannon AW.
Icagen Inc., P.O. Box 14487,
Research Triangle Park, NC 27709, USA.
Curr Opin Pharmacol. 2008 Feb;8(1):50-6.
ABSTRACTRecent scientific advances have enhanced our understanding of the role voltage-gated sodium channels play in pain sensation. Human data on Nav1.7 show that gain-of-function mutations lead to enhanced pain while loss-of-function mutations lead to Congenital Indifference to Pain. Pre-clinical data from knockouts, anti-sense oligonucleotides, and siRNA for Nav1.3, 1.7, 1.8, and 1.9 have also demonstrated that specific subtypes of voltage-gated sodium channels play a role in different types of pain signaling. In addition, recent reports show that CNS penetration by voltage-gated sodium channel blockers is not required for efficacy in pre-clinical pain models while others have reported that identification of subtype-selective small molecules is possible. All of these data are converging to suggest next generation sodium channel blockers may offer the potential for novel pain therapies in the future.Eugenics talk
Selecting potential children
Mood genes and human nature
Preimplantation genetic diagnosis
'A life without pain? Hedonists take note'
Francis Galton and contemporary eugenics
Inherited neuronal ion channelopathies and pain
The neurological basis of the emotional dimension of pain
and further reading
The Good Drug Guide
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
MDMA: Utopian Pharmacology
Critique of Huxley's Brave New World